Sign in →

Test Code CSMHP Controlled Substance Monitoring Hybrid Plus Drug Profile, 19 Drug Classes, High-Resolution Mass Spectrometry and Immunoassay Screen, Random, Urine


Ordering Guidance


This test does not screen for drug classes other than those listed in Reference Values.



Specimen Required


Supplies: Urine Container, 60 mL (T313)

Collection Container/Tube: Plastic urine container

Submission Container/Tube: Plastic, 60-mL urine container

Specimen Volume: 30 mL

Collection Instructions:

1. Collect a random urine specimen.

2. Submit 30 mL in 1 plastic bottle.

3. No preservative.

Additional Information:

1. No specimen substitutions.

2. Submitting less than 30 mL may compromise the ability to perform all necessary testing.

3. STAT requests are not accepted for this test.


Forms

If not ordering electronically, complete, print, and send 1 of the following forms with the specimen:

-Therapeutics Test Request (T831)

-Kidney Transplant Test Request

Useful For

Detecting drug use involving stimulants, benzodiazepines, cocaine, opioids, and gabapentinoids.

 

Clinical monitoring or management of patients

 

This test is not intended for use in employment-related testing.

Profile Information

Test ID Reporting Name Available Separately Always Performed
LPCM List Patient's Current Medications No Yes
ADULT Adulterants Survey, U Yes Yes
SCOCA Cocaine IA Screen, U No Yes
TOPU Targeted Opioid MS Screen, U Yes, (Order TOSU) Yes
TABSU Targeted Benzodiazepine Screen, U Yes, (Order TBSU) Yes
TSIM Gabapentinoid/Stim MS Screen, U Yes, (Order TGSU) Yes

Testing Algorithm

Testing begins with an adulterant survey. If the sample is found to be adulterated, testing will end and the remaining tests will be canceled.

 

If the specimen is normal or only diluted, remaining testing will continue.

 

Positive results can be confirmed and quantitated by gas chromatography mass spectrometry for cocaine and metabolites at an additional charge.

Method Name

ADULT: Spectrophotometry (SP)

SCOCA: Immunoassay

TABSU, TOPU, TSIM: Liquid Chromatography Tandem Mass Spectrometry, High-Resolution Accurate Mass (LC-MS/MS HRAM)

Reporting Name

CSM Hybrid Plus,19, HRMS/IA, U

Specimen Type

Urine

Specimen Minimum Volume

20 mL

Specimen Stability Information

Specimen Type Temperature Time
Urine Refrigerated (preferred) 14 days
  Frozen  14 days

Reject Due To

  All specimens will be evaluated at Mayo Clinic Laboratories for test suitability.

Clinical Information

The cocaine screen portion uses immunoassay screening techniques. A positive immunoassay screening result can be confirmed by gas chromatography mass spectrometry and quantitated at an additional charge.

 

The targeted opioid, benzodiazepine, and stimulant screen portions are performed using liquid chromatography tandem mass spectrometry, high-resolution accurate mass and are completed for all opioids, benzodiazepines, and stimulants. Opioids are a large class of medications commonly used to relieve acute and chronic pain or help manage opioid abuse and dependence. Medications that fall into this class include buprenorphine, codeine, fentanyl, hydrocodone, hydromorphone, methadone, morphine, oxycodone, oxymorphone, tapentadol, tramadol, and others. Opioids work by binding to the opioid receptors that are found in the brain, spinal cord, gastrointestinal tract, and other organs. Common side effects for opioids include drowsiness, confusion, nausea, constipation, and, in severe cases, respiratory depression. These are dose dependent and vary with tolerance. These medications can also produce physical and psychological dependence and have a high risk for abuse and diversion, which is one of the main reasons many professional practice guidelines recommend compliance testing in patients prescribed these medications.

 

Opioids are readily absorbed from the gastrointestinal tract, nasal mucosa, lungs, and after subcutaneous or intermuscular injection. Opioids are primarily excreted from the kidney in both free and conjugated forms. This assay does not hydrolyze the urine sample and looks for both parent drugs and metabolites (including glucuronide forms). The detection window for most opioids in urine is approximately 1 to 3 days with longer detection times for some compounds (ie, methadone).

 

Benzodiazepines represent a large family of medications used to treat a wide range of disorders from anxiety to seizures and are also used in pain management. With a high risk for abuse and diversion, professional practice guidelines recommend compliance monitoring for these medications using urine drug tests. However, traditional benzodiazepine immunoassays suffer from a lack of cross-reactivity with all the benzodiazepines, so many compliant patients taking either clonazepam (Klonopin) or lorazepam (Ativan) may screen negative by immunoassay but are positive when confirmatory testing is done. The new targeted benzodiazepine screening test provides a more sensitive and specific test to check for compliance to all the commonly prescribed benzodiazepines and looks for both parent drugs and metabolites in the urine.

 

Stimulants are sympathomimetic amines that stimulate the central nervous system activity and, in part, suppress the appetite. Amphetamine and methamphetamine are also prescription drugs used in the treatment of narcolepsy and attention-deficit disorder/attention-deficit hyperactivity disorder (ADHD). Methylphenidate is another stimulant used to treat ADHD. Phentermine is indicated for the management of obesity. All other amphetamines (eg, methylenedioxymethamphetamine: MDMA) are Drug Enforcement Administration-scheduled Class I compounds. Due to their stimulant effects, the drugs are commonly sold illicitly and abused. Physiological symptoms associated with very high amounts of ingested amphetamine or methamphetamine include elevated blood pressure, dilated pupils, hyperthermia, convulsions, and acute amphetamine psychosis.

 

Gabapentinoids (pregabalin, gabapentin) are widely used in neurology, psychiatry, and primary care, with increasing reports of misuse. They decrease central neuronal excitability by binding to the calcium channel of hyperexcited neurons which results in a reduction in the release of excitatory molecules including glutamate and noradrenaline. Gabapentin is not metabolized or protein bound and is primarily excreted and detectable in the urine for up to four days. Pregabalin is also largely excreted unchanged in the urine and detectable for up to 6 days.

 

This test is intended to be used in a setting where the test results can be used to make a definitive diagnosis.

Reference Values

ADULTERANT SURVEY:

Cutoff concentrations

Oxidants: 200 mg/L

Nitrites: 500 mg/L

 

COCAINE IMMUNOASSAY SCREEN:

Negative

Screening cutoff concentrations:

Cocaine (benzoylecgonine-cocaine metabolite): 150 ng/mL

 

TARGETED OPIOID MASS SPECTROMETRY SCREEN:

Not detected (Positive results are reported with qualitative "Present" results)

 

Cutoff concentrations:

Codeine: 25 ng/mL

Codeine-6-beta-glucuronide: 100 ng/mL

Morphine: 25 ng/mL

Morphine-6-beta-glucuronide: 100 ng/mL

6-Monoacetylmorphine: 25 ng/mL

Hydrocodone: 25 ng/mL

Norhydrocodone: 25 ng/mL

Dihydrocodeine: 25 ng/mL

Hydromorphone: 25 ng/mL

Hydromorphone-3-beta-glucuronide: 100 ng/mL

Oxycodone: 25 ng/mL

Noroxycodone: 25 ng/mL

Oxymorphone: 25 ng/mL

Oxymorphone-3-beta-glucuronide: 100 ng/mL

Noroxymorphone: 25 ng/mL

Fentanyl: 2 ng/mL

Norfentanyl: 2 ng/mL

Meperidine: 25 ng/mL

Normeperidine: 25 ng/mL

Naloxone: 25 ng/mL

Naloxone-3-beta-glucuronide: 100 ng/mL

Methadone: 25 ng/mL

2-Ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP): 25 ng/mL

Tramadol: 25 ng/mL

O-desmethyltramadol: 25 ng/mL

Tapentadol: 25 ng/mL

N-desmethyltapentadol: 50 ng/mL

Tapentadol-beta-glucuronide: 100 ng/mL

Buprenorphine: 5 ng/mL

Norbuprenorphine: 5 ng/mL

Norbuprenorphine glucuronide: 20 ng/mL

 

TARGETED BENZODIAZEPINE MASS SPECTROMETRY SCREEN:

Not detected (Positive results are reported with qualitative "Present" results)

 

Cutoff concentrations:

Alprazolam: 10 ng/mL

Alpha-hydroxyalprazolam: 10 ng/mL

Alpha-hydroxyalprazolam glucuronide: 50 ng/mL

Chlordiazepoxide: 10 ng/mL

Clobazam: 10 ng/mL

N-desmethylclobazam: 200 ng/mL

Clonazepam: 10 ng/mL

7-Aminoclonazepam: 10 ng/mL

Diazepam: 10 ng/mL

Nordiazepam: 10 ng/mL

Flunitrazepam: 10 ng/mL

7-Aminoflunitrazepam: 10 ng/mL

Flurazepam: 10 ng/mL

2-Hydroxy ethyl flurazepam: 10 ng/mL

Lorazepam: 10 ng/mL

Lorazepam glucuronide: 50 ng/mL

Midazolam: 10 ng/mL

Alpha-hydroxymidazolam: 10 ng/mL

Oxazepam: 10 ng/mL

Oxazepam glucuronide: 50 ng/mL

Prazepam: 10 ng/mL

Temazepam: 10 ng/mL

Temazepam glucuronide: 50 ng/mL

Triazolam: 10 ng/mL

Alpha-hydroxytriazolam: 10 ng/mL

Zolpidem: 10 ng/mL

Zolpidem phenyl-4-carboxylic acid: 10 ng/mL

 

TARGETED GABAPENTINOID AND STIMULANT MASS SPECTROMETRY SCREEN:

Not detected (Positive results are reported with qualitative "Present" results)

 

Cutoff concentrations:

Methamphetamine: 100 ng/mL

Amphetamine: 100 ng/mL

3,4-Methylenedioxymethamphetamine (MDMA): 100 ng/mL

3,4-Methylenedioxy-N-ethylamphetamine (MDEA): 100 ng/mL

3,4-Methylenedioxyamphetamine (MDA): 100 ng/mL

Ephedrine: 100 ng/mL

Pseudoephedrine: 100 ng/mL

Phentermine: 100 ng/mL

Phencyclidine (PCP): 20 ng/mL

Methylphenidate: 20 ng/mL

Ritalinic acid: 100 ng/mL

Gabapentin: 500 ng/mL

Pregabalin: 500 ng/mL

Day(s) Performed

Monday through Saturday

Report Available

3 to 4 days

Specimen Retention Time

14 days

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information

80307

G0482

80326 (if appropriate for select payers)

80347 (if appropriate for select payers)

80364 (if appropriate for select payers)

Clinical Toxicology CPT Code Client Guidance

LOINC Code Information

Test ID Test Order Name Order LOINC Value
CSMHP CSM Hybrid Plus,19, HRMS/IA, U 69739-1

 

Result ID Test Result Name Result LOINC Value
LPCM List Patient's Current Medications 66423-5
624198 Methamphetamine 19554-5
20606 Creatinine, U 2161-8
604871 Alprazolam 94116-1
624246 Cocaine 19359-9
624213 Codeine 19411-8
624214 Codeine-6-beta-glucuronide 89310-7
604867 Alpha-Hydroxyalprazolam 19325-0
22312 Specific Gravity 5810-7
624199 Amphetamine 19343-3
624200 3,4-methylenedioxymethamphetamine (MDMA) 19568-5
23509 pH 2756-5
604891 Alpha-Hydroxyalprazolam Glucuronide 94115-3
624215 Morphine 19597-4
624216 Morphine-6-beta-glucuronide 89308-1
604872 Chlordiazepoxide 19385-4
23511 Oxidants 58714-7
624201 3,4-methylenedioxy-N-ethylamphetamine (MDEA) 59844-1
624202 3,4-methylenedioxyamphetamine (MDA) 19565-1
23510 Nitrites 32710-6
604889 Clobazam 94114-6
624217 6-monoacetylmorphine 19321-9
624218 Hydrocodone 19482-9
604890 N-Desmethylclobazam 94113-8
30914 Comment 48767-8
624203 Ephedrine 99108-3
624204 Pseudoephedrine 99109-1
604873 Clonazepam 19399-5
624219 Norhydrocodone 89304-0
624220 Dihydrocodeine 19446-4
604267 7-aminoclonazepam 94112-0
624205 Phentermine 19674-1
624206 Phencyclidine (PCP) 19659-2
604874 Diazepam 19443-1
624221 Hydromorphone 19486-0
624222 Hydromorphone-3-beta-glucuronide 89309-9
604880 Nordiazepam 19624-6
624207 Methylphenidate 19577-6
624208 Ritalinic acid 99110-9
604875 Flunitrazepam 19466-2
624223 Oxycodone 19642-8
624224 Noroxycodone 89303-2
604866 7-aminoflunitrazepam 94111-2
624209 Gabapentin 68439-9
624210 Pregabalin 105953-4
604876 Flurazepam 19474-6
624225 Oxymorphone 19646-9
624226 Oxymorphone-3-beta-glucuronide 89301-6
604868 2-Hydroxy Ethyl Flurazepam 94110-4
624211 Stimulant Interpretation 54247-2
604877 Lorazepam 19520-6
624227 Noroxymorphone 89302-4
624228 Fentanyl 59673-4
604878 Lorazepam Glucuronide 94109-6
604879 Midazolam 19585-9
624229 Norfentanyl 43199-9
624230 Meperidine 19532-1
604869 Alpha-Hydroxy Midazolam 94108-8
604881 Oxazepam 19638-6
624231 Normeperidine 27920-8
624232 Naloxone 42618-9
604882 Oxazepam Glucuronide 94107-0
604883 Prazepam 19678-2
624233 Naloxone-3-beta-glucuronide 89307-3
624234 Methadone 19550-3
604884 Temazepam 19698-0
604885 Temazepam Glucuronide 94106-2
624235 EDDP 93495-0
624236 Tramadol 19710-3
604886 Triazolam 19714-5
604870 Alpha-Hydroxy Triazolam 94105-4
624237 O-desmethyltramadol 86453-8
624238 Tapentadol 72485-6
604887 Zolpidem 94104-7
604888 Zolpidem Phenyl-4-Carboxylic acid 94103-9
624239 N-desmethyltapentadol 89306-5
624240 Tapentadol-beta-glucuronide 89300-8
604949 Benzodiazepine Interpretation 69050-3
624241 Buprenorphine 93494-3
624242 Norbuprenorphine 82371-6
624243 Norbuprenorphine glucuronide 89305-7
624244 Opioid Interpretation 69050-3